Pharmaceutical companies face rising R&D costs, AI-native competitors moving faster through discovery and trials, and legacy systems that keep clinical, manufacturing, and safety data stuck in silos.
This whitepaper maps how AI is being applied, and where it delivers measurable ROI, across all 11 stages of the pharmaceutical value chain, from early drug discovery through post-market pharmacovigilance.
You’ll find quantified ROI benchmarks, landmark case studies from Insilico, Exscientia, Roche, and others, a stage-by-stage Germany vs US regulatory comparison, and guidance on the data foundation Adastra can help you build to make pharma AI actually work.
What Will You Learn?
You’ll learn how to:
- Pinpoint where AI delivers the highest ROI across the value chain — from $6M AI-designed drugs to 70% clinical trial cost reductions
- Build the AI-ready data infrastructure needed to move pilots into GxP-compliant, production-grade deployments
- Prepare for regulatory scrutiny under FDA, EMA, and the EU AI Act’s high-risk classification for drug development AI
- Compare where Germany and the US diverge and converge on AI adoption, from AMNOG to decentralized trials
- Understand what’s driving the 42% failure rate of pharma AI initiatives, and how to avoid it
- Identify high-impact, low-risk AI use cases and build the case for investment with your leadership team
Why Adastra?
Adastra is a global AI, data, and cloud consulting and implementation firm trusted by leading pharmaceutical and life sciences companies, including AstraZeneca, GSK, and Apotex. For 25+ years, regulated industries have relied on us to build compliant data foundations that unlock AI at scale, with typical AI project ROI in 3 to 6 months.
Our pharma AI practice spans data platform architecture, AI model implementation, Computer System Validation support, and GxP governance design, helping you turn AI pilots into audit-ready, production-grade systems, wherever you’re starting from.
